Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Jens-Otto Andreas"'
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics. 43:475-481
Pharmacokinetic studies using deconvolution methods and non-compartmental analysis to model clinical absorption of drugs are not well represented in the literature. The purpose of this research was (1) to define the system of equations for descriptio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09e813cde46443ec3884ff197bdfce6e
https://doi.org/10.1007/s13318-018-0460-3
https://doi.org/10.1007/s13318-018-0460-3
Publikováno v:
Journal of Clinical Psychopharmacology. 37:675-683
PURPOSE This phase 1, randomized, double-blind, placebo- and active comparator-controlled crossover study assessed the abuse potential of the antiepileptic drug, lacosamide. METHODS After a qualification phase, 38 healthy, recreational central nervou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::132623aa700ad8bca42375a5b1f5014f
https://doi.org/10.1097/jcp.0000000000000780
https://doi.org/10.1097/jcp.0000000000000780
Autor:
Kyung Sang Yu, Marina Braun, Jens Otto Andreas, In-Jin Jang, Jung-Ryul Kim, Bo Hyung Kim, Willi Cawello, Jan Peer Elshoff, Kyoung Soo Lim
Publikováno v:
Clinical Therapeutics. 37:902-912
Purpose Rotigotine, a nonergolinic dopamine receptor agonist, is a once-daily transdermal patch developed for the treatment of Parkinson's disease and restless legs syndrome. The objective of the present study was to determine the pharmacokinetic cha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cc71b72e398ab09ba3df98d91c00819
https://doi.org/10.1016/j.clinthera.2015.01.013
https://doi.org/10.1016/j.clinthera.2015.01.013
Autor:
Katsumi Yamamoto, Shikiko Watanabe, Malcolm Boyce, Nathalie Toublanc, Katsumi Yoshida, Jens-Otto Andreas, Takuya Okagaki, Robert Chan, Ayumi Mugitani
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics. 40:461-469
The intravenous (iv) formulation of levetiracetam has been available in clinical practice worldwide for several years, but not in Japan. Two open-label studies were conducted: Study A evaluated the bioequivalence of iv and oral tablet formulations in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c79fa8753019c78a19ae26ccfbe58d67
https://doi.org/10.1007/s13318-014-0227-4
https://doi.org/10.1007/s13318-014-0227-4
Publikováno v:
Annals of the New York Academy of Sciences. 1329:18-32
Lacosamide (LCM) is a functionalized amino acid specifically developed for use as an antiepileptic drug (AED) and is currently indicated as adjunctive treatment for partial-onset seizures in adults with focal epilepsy (maximum approved dose 400 mg/da
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::060016a8aa0becaff0e1bc0b7ea5c203
https://doi.org/10.1111/nyas.12513
https://doi.org/10.1111/nyas.12513
Publikováno v:
Clinical Pharmacology in Drug Development. 3:187-193
Rotigotine, a non-ergolinic dopamine receptor agonist administered transdermally via a patch, is metabolized by several cytochrome P-450 (CYP450) isoenzymes, including CYP2C19. This open-label, multiple-dose study evaluated the effect of omeprazole,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::63b019f07042d20b770cf7bab4c1e2c0
https://doi.org/10.1002/cpdd.78
https://doi.org/10.1002/cpdd.78
Publikováno v:
Epilepsia. 54:81-88
Summary Purpose: To test for bioequivalence of 200 mg lacosamide oral tablet and syrup formulations. Additional objectives were to compare the pharmacokinetic profile of lacosamide in saliva and plasma, and to evaluate its tolerability. Methods: This
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9d3a7df7cee2cbda02238ae3b12fe9eb
https://doi.org/10.1111/j.1528-1167.2012.03725.x
https://doi.org/10.1111/j.1528-1167.2012.03725.x
Publikováno v:
British Journal of Clinical Pharmacology. 68:386-394
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • The non-ergolinic dopamine agonist rotigotine was developed for the treatment of Parkinson's disease and restless legs syndrome as a silicone-based matrix-type transdermal system. • Dopamine agonists hav
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b36f285520e93bcab181f700adc3273a
https://doi.org/10.1111/j.1365-2125.2009.03468.x
https://doi.org/10.1111/j.1365-2125.2009.03468.x
Publikováno v:
Annals of the New York Academy of Sciences. 1329
Lacosamide (LCM) is a functionalized amino acid specifically developed for use as an antiepileptic drug (AED) and is currently indicated as adjunctive treatment for partial-onset seizures in adults with focal epilepsy (maximum approved dose 400 mg/da
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6976aa3303bcc74cafafd715775c702d
https://pubmed.ncbi.nlm.nih.gov/25167889
https://pubmed.ncbi.nlm.nih.gov/25167889
Publikováno v:
Clinical drug investigation. 34(5)
Recent data suggest that P-glycoprotein may be involved in cellular transport of lacosamide. To investigate potential drug–drug interactions (DDIs) between lacosamide and digoxin, this phase I, multiple-dose, randomised, double-blind, placebo-contr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5add13449d233baae7f26da7399f49c7
https://pubmed.ncbi.nlm.nih.gov/24634110
https://pubmed.ncbi.nlm.nih.gov/24634110